Frequently Asked Questions
The global hydatid disease treatment market was valued at USD XX million in 2022.
The hydatid disease treatment market is expected to grow at a CAGR of 5.6% between 2023 and 2030, reaching USD XX million in 2030.
Medical treatment is the leading segment by treatment type, holding over 58% share in value in 2022.
The hepatic hydatid disease (infection in the liver) segment governs the global demand for hydatid disease treatment, holding a massive share of over 40% in 2022.
The surgical centers segment will post the highest CAGR over the projection period.
North America is fueling the robust growth of the hydatid disease treatment industry, with over one-third of its share in 2022.
The top players include Amneal Pharmaceuticals LLC, GSK Plc, Abbott Laboratories Inc, Merck KGaA, Janssen Global Services LLC (Johnson & Johnson Services Inc), Lupin Limited, Cadila Pharmaceuticals Limited, Zydus Group, Mankind Pharma, Ipca Laboratories Ltd, and Others.
The major market drivers of the hydatid disease treatment industry include high disease prevalence in endemic regions and continuous advancements in treatment modalities.
The major market restraints of the hydatid disease treatment industry include limited access to healthcare in rural areas and the potential for drug resistance and cyst recurrence.
The major market opportunities of the hydatid disease treatment industry include the adoption of telemedicine and telehealth solutions and ongoing research into novel therapies for more effective treatment options.